Clinical Trial Update: FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating FR901228 in pediatric patients with refractory or recurrent solid tumors or leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Astrocytoma High Grade
• Central Nervous System Germ Cell Tumor
• Chronic Myeloid Leukemia
• Craniopharyngioma
• Ependymoma
• Medulloblastoma
• Meningioma
• Primitive Neuroectodermal Tumor

Drugs mentioned

• FR901228 (romidepsin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Blastic Phase Chronic Myelogenous Leukemia, Childhood Central Nervous System Germ Cell Tumor | Phase 1 | Status: COMPLETED